Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document Novartis submission schedule New Molecular Entities: Lead and supplementary indications Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations References Lead Supplementary 2024 atrasentan EXV811 IgAN remibrutinib LOU064 CSU iptacopan LNP023 C3G iptacopan LNP023 IgAN ۱۲۳۴ 2025 pelacarsen TQJ230 CVRR-Lp(a) INNOVATION CRM Immunology Neuroscience Oncology Non-core TA project 2026 ≥2027 ianalumab VAY736 2L Immune Thrombocytopenia XXB750 Hypertension ۱۳ zigakibart It's 177Lu-NeoB AAA603 Multiple Solid Tumors iscalimab CFZ533 Sjögren's syndrome ligelizumab QGE031 Food allergy LNA043 Knee osteoarthritis opnurasib JDQ443 NSCLC (mono/combo) rapcabtagene autoleucel YTB323 High-risk large B-cell lymphoma FUB523 IgAN ganaplacide/lumefantrine KLU156 Malaria uncomplicated cipargamin KAE609 Malaria severe LXE408 Visceral leishmaniasis ianalumab VAY736 1L Immune Thrombocytopenia ianalumab VAY736 WAIHA ianalumab VAY736 AIH ianalumab VAY736 SLE iptacopan LNP023 aHUS ianalumab VAY736 Lupus Nephritis iptacopan LNP023 IC-MPGN rapcabtagene autoleucel YTB323 srSLE/LN remibrutinib LOU064 Multiple sclerosis remibrutinib LOU064 CINDU ianalumab VAY736 Sjögren's syndrome □ NOVARTIS Reimagining Medicine | cipargamin KAE609 Malaria uncomplicated Novartis Q4 Results | January 31, 2024 42

View entire presentation